COM-002

COM-002 is a first-in-class complement-powered immune engager developed by Commit Biologics using its proprietary Bispecific Complement Engager (BiCE™) platform. The antibody-based candidate is designed to harness the classical complement pathway by recruiting the complement protein C1q to target cells, triggering complement activation and immune-mediated cell killing exclusively upon target engagement. This approach provides an alternative to T-cell-engaging therapies, operating independently of T-cell function and presence, thereby reducing the risk of cytokine release syndrome. COM-002 is in preclinical development, initially targeting relapsed or refractory non-Hodgkin lymphoma (NHL) through targeted B-cell depletion, with plans to expand into several autoimmune indications. First-in-human Phase 1 clinical trials are anticipated to begin in early 2028.